The procedure, called Uterine Transposition, consists on temporarily suspending the uterus in the abdomen so the patient can receive radiation without affecting it ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

Yale study reveals cultural influences in breast cancer surgery decisions, focusing on challenges faced by women of color post-mastectomy.

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...

SKOPJE – A bottleneck in health-care services is causing dangerous delays in the diagnosis and treatment of breast cancer in ...

Altamonte Springs, Fla.-based AdventHealth has launched a pilot program designed to harness AI to assess a patient's risk of developing breast cancer. The Genomics Risk Assessment for Cancer and Early ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...

Virologist Beata Halassy says self-treatment worked and was a positive experience — but researchers warn that it is not ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...